What are the cardiovascular effects of the newer classes of drugs for type 2 diabetes?

New classes of drugs to treat type 2 diabetes are continually being developed and marketed. The FDA has issued guidance to the pharmaceutical industry that newer hypoglycemic agents should not be associated with unacceptable increases in cardiovascular risk. To date, five trials have assessed specific cardiovascular endpoints for these newer agents. Empagliflozin and liraglutide have been found to improve cardiovascular outcomes.
Source: Journal of the American Academy of Physician Assistants - Category: Primary Care Tags: Pharmacology Consult Source Type: research